Galmed Pharmaceuticals (GLMD) News Today $0.31 +0.01 (+3.29%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 21, 2024 | americanbankingnews.comGalmed Pharmaceuticals (NASDAQ:GLMD) Receives New Coverage from Analysts at StockNews.comJune 22, 2024 | investorplace.comGLMD Stock Earnings: Galmed Pharmaceuticals Reported Results for Q1 2024April 13, 2024 | fool.comGalmed Pharmaceuticals (NASDAQ: GLMD)April 10, 2024 | investorplace.comWall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024April 4, 2024 | prnewswire.comGalmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023March 15, 2024 | markets.businessinsider.comGalmed Granted European Patent For Use Of Aramchol-Resmetirom To Treat NASH/MASH, Liver FibrosisMarch 15, 2024 | prnewswire.comGalmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver FibrosisFebruary 13, 2024 | uk.finance.yahoo.comGalmed Pharmaceuticals Ltd (GPH.BE)January 3, 2024 | uk.finance.yahoo.comGalmed Pharmaceuticals Ltd. (GPH.F)November 20, 2023 | finance.yahoo.comGalmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a StudyNovember 4, 2023 | morningstar.comGalmed Pharmaceuticals Ltd GLMDSeptember 26, 2023 | finance.yahoo.comGalmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal FibrosisAugust 3, 2023 | nasdaq.comGalmed Pharmaceuticals (GLMD) Price Target Increased by 300.00% to 4.08July 14, 2023 | marketwatch.comGalmed Pharma Shares Drop 30% After Public Offering PricesJuly 14, 2023 | seekingalpha.comGalmed shares slump on pricing discounted stock and warrants offeringJuly 14, 2023 | finance.yahoo.comGalmed Pharmaceuticals Announces Pricing of $7 Million Public OfferingJuly 14, 2023 | marketbeat.comTrading was temporarily halted for "GLMD" at 09:07 AM with a stated reason of "LULD pause."July 13, 2023 | investorplace.comWhy Is Galmed Pharmaceuticals (GLMD) Stock Moving Today?July 12, 2023 | marketbeat.comTrading was temporarily halted for "GLMD" at 12:07 PM with a stated reason of "LULD pause." Trading set to resume at 12:07 PM. July 12, 2023 | marketbeat.comTrading was temporarily halted for "GLMD" at 12:07 PM with a stated reason of "LULD pause."July 12, 2023 | marketbeat.comTrading was temporarily halted for "GLMD" at 12:07 PM with a stated reason of "LULD pause."July 10, 2023 | finance.yahoo.comGalmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSCJuly 3, 2023 | bizjournals.comMadrigal begins process seeking OK for multibillion-dollar — yet elusive — NASH drugJune 3, 2023 | benzinga.comGalmed Pharmaceuticals Stock (NASDAQ:GLMD), Insider Trading ActivityJune 1, 2023 | finanznachrichten.deGalmed Pharmaceuticals Ltd.: Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent DevelopmentsJune 1, 2023 | msn.comRecap: Galmed Pharmaceuticals Q1 EarningsJune 1, 2023 | finance.yahoo.comGalmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent DevelopmentsMay 17, 2023 | thestreet.comWhy Galmed Pharmaceuticals (GLMD) Stock Is Surging TodayMay 11, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Galmed Pharmaceuticals (GLMD) and Haemonetics (HAE)May 9, 2023 | finance.yahoo.comGalmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC)May 5, 2023 | msn.comWhy Is Galmed Pharmaceuticals (GLMD) Stock Up 37% Today?May 4, 2023 | finance.yahoo.comGalmed Pharmaceuticals forms a Strategic Partnership with OnKaiMarch 29, 2023 | finance.yahoo.comGalmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022February 17, 2023 | seekingalpha.comGLMD Galmed Pharmaceuticals Ltd.February 8, 2023 | finance.yahoo.comGalmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine SaltJanuary 6, 2023 | finance.yahoo.comCan Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?January 4, 2023 | marketwatch.comGalmed Pharmaceuticals Shares Up 9.2% on Data From Liver Treatment Aramchol StudyJanuary 4, 2023 | finance.yahoo.comGalmed reports results from the Open-Label part of the ARMOR study showing improvements in histology, imaging, and biomarkers with AramcholDecember 14, 2022 | finance.yahoo.comGalmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price RequirementSeptember 14, 2022 | finance.yahoo.comGalmed Pharmaceuticals (GLMD) Moves to Buy: Rationale Behind the UpgradeAugust 4, 2022 | finance.yahoo.comGalmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial ResultsJuly 7, 2022 | finance.yahoo.comGalmed's Aramchol Shows Anti-Fibrotic Effects In Lung Fibrosis Animal ModelJuly 7, 2022 | nasdaq.comGalmed: New Data Reinforces Expansion Of Aramchol's Clinical Development To Additional IndicationsJuly 7, 2022 | finance.yahoo.comGalmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis ModelJune 17, 2022 | finance.yahoo.comGalmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price NotificationMay 25, 2022 | benzinga.comGalmed Pharmaceuticals (NASDAQ:GLMD), Analyst Ratings, Price Targets, PredictionsMay 18, 2022 | seekingalpha.comGalmed Pharmaceuticals shares fall after downgrade by Raymond James analystMay 17, 2022 | finance.yahoo.comGalmed updates business and clinical development strategy to better leverage Aramchol's anti-fibrotic effectsMay 17, 2022 | finance.yahoo.comGalmed Pharmaceuticals Reports First Quarter 2022 Financial ResultsMay 3, 2022 | marketwatch.comGalmed Pharmaceuticals Shares Down 16% Get Galmed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter. Email Address 625,000% Gain (Ad)Imagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz. >> Dive into the Workshop Here GLMD Media Mentions By Week GLMD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GLMD News Sentiment▼0.290.62▲Average Medical News Sentiment GLMD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GLMD Articles This Week▼30▲GLMD Articles Average Week Get Galmed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SNGX News Today HEPA News Today TFFP News Today SNOA News Today HUGE News Today SNPX News Today RNAZ News Today LIXT News Today BFRI News Today VIRI News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GLMD) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galmed Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galmed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.